Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

St. Jude Halts U.S. Renal Denervation Trial, Citing Slow Patient Enrollment

This article was originally published in The Gray Sheet

Executive Summary

Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.

You may also be interested in...



SYMPLICITY Results Make Life Difficult For Renal Denervation Programs

The big slice of the device industry, from large-cap firms to venture capitalists, with some stake in the renal denervation opportunity are trying to understand the new reality now that Medtronic’s pivotal Symplicity renal denervation device trial missed its endpoint.

Covidien Quits Renal Denervation Race; Others Stick It Out, For Now

A Covidien executive said in an interview that the firm’s decision to halt development of its OneShot renal denervation system was made prior to Medtronic’s recent announcement that its Symplicity device missed its endpoint. Covidien cites slower-than-expected development of the renal denervation market.

Symplicity Makes Life Difficult For Renal Denervation Programs

A big slice of the device industry, from large-cap firms to venture capitalists, is trying to understand the new reality in the wake of Medtronic’s announcement that its Symplicity hypertension trial missed its endpoint

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT032692

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel